Key Metrics
CiteScore 

4
H-Index 

59
Impact Factor 

< 5
SJR 

Q2Hematology

SNIP 

1.05
Recommended pre-submission checks
Powered by 

Topics Covered on Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis Journal Specifications
| Overview | |
| Publisher | SAGE PUBLICATIONS INC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2500 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 1995 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Clinical and Applied Thrombosis/Hemostasis ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Clinical and Applied Thrombosis/Hemostasis
Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Knowledge Drives Venous Thromboembolism Prevention: Structural Equation Modeling Insights Into Physicians\u2019 Knowledge, Attitudes and Practices in Chinese Public Hospitals
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Upregulation of Serum miRNA-3615 Serves as a Biomarker to Predict Disease Onset and Prognosis in Acute Coronary Syndrome Patients
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries \u2013 For Whom, by Whom and Where?
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
LncRNA HOXA11-AS Promotes Myocardial Injury in Chronic Heart Failure by Sponging miR-342-3p
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population
- 9 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Knowledge Drives Venous Thromboembolism Prevention: Structural Equation Modeling Insights Into Physicians\u2019 Knowledge, Attitudes and Practices in Chinese Public Hospitals
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Upregulation of Serum miRNA-3615 Serves as a Biomarker to Predict Disease Onset and Prognosis in Acute Coronary Syndrome Patients
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries \u2013 For Whom, by Whom and Where?
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
LncRNA HOXA11-AS Promotes Myocardial Injury in Chronic Heart Failure by Sponging miR-342-3p
- 11 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis
Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population
- 9 Jun 2026
- Clinical and Applied Thrombosis/Hemostasis